Current Approaches For new TB Drugs

ISSN: 1875-6387 (Online)
ISSN: 1573-398X (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Respiratory Medicine Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Joseph Varon
The University of Texas Health Science Center
Houston, TX
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Current Approaches For new TB Drugs

Author(s): Shilpika Pandey, Isha Soni, Neha Topno, Arunava Dasgupta and Sidharth Chopra

Affiliation: Senior Scientist, Division of Microbiology, CSIR-Central Drug Research Institute B.S. 10/1, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow - 226031, India.

Abstract

Tuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.


Purchase Online Rights and Permissions

  
  



Article Details

Volume: 10
First Page: 1
Page Count: 1
DOI: 10.2174/1573398X10666140813201210
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science